Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to ...

BiTAC® is a registered trademark of VERAXA Biotech GmbH.

Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...

Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

Researchers at Karolinska Institutet have uncovered how serotonin-related metabolism helps regulate an understudied immune ...

Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing ...

The Royal Navy has launched a lethal drone strike while out at sea in a series of landmark trials. A Nyan One Way Effector ...

This gentleman opened my eyes to this agent in 2020 when I was furiously researching anything and everything that might save ...

To secure mission dominance in a future, contested environment, the Joint Force must make decisions faster than any adversary. This imperative was the driving force behind the Multi-Decision Advantage ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...